3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase NA
2
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
147
Breast Neoplasms
116
Prostatic Neoplasms
61
Multiple Myeloma
57
Neoplasms
56
Lung Neoplasms
50
Neoplasm Metastasis
43
Ovarian Neoplasms
36
Parkinson Disease 4, Autosomal Dominant Lewy Body
35
Colorectal Neoplasms
34
Leukemia, Lymphocytic, Chronic, B-Cell
33
Carcinoma, Renal Cell
27
Recurrence
26
Leukemia, Myeloid, Acute
26
Urinary Bladder Neoplasms
25
Carcinoma, Hepatocellular
24
Small Cell Lung Carcinoma
23
Myasthenia Gravis
22
Triple Negative Breast Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
20
Lymphoma, Large B-Cell, Diffuse
20
Endometrial Neoplasms
20
Melanoma
19
Lymphoma, Follicular
19
Nasopharyngeal Carcinoma
18
Fallopian Tube Neoplasms
18
Stomach Neoplasms
17
Non-Muscle Invasive Bladder Neoplasms
16
Brain Neoplasms
16
Pancreatic Neoplasms
15
Interventions
palbociclib
1
lenvatinib
1
cabozantinib
1
belzutifan
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
von Hippel-Lindau Disease
×
90 days
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled